Natco Pharma receives Delhi HC approval to launch Chlorantraniliprole; stock climbs ~2.5%

20 Sep 2022 , 09:25 AM

Natco Pharma Limited received an order from the Hon’ble High Court of Delhi stating that NATCO is permitted to launch Chlorantraniliprole (CTPR) and its formulations using their non-infringing technology.

NATCO is India’s first company to get registration clearance from the Central Insecticide Board and Registration Committee (CIB&RC) for indigenous manufacture of Chlorantraniliprole (CTPR) Technical 93.00% w/w min.

CTPR technology is compounded into broad-spectrum insecticides that are used to control pests in a variety of crops.

NATCO believes that the existing market for CTPR-containing products in India is worth more than Rs2,000 crore. The company intends to release its products very soon.

At around 9.27 AM, Natco Pharma was trading at Rs652.55 per piece, up by 2.38% from its previous closing of Rs637.40 on the BSE. The scrip opened at Rs653 and touched intraday high and low of Rs660 and Rs648.95 respectively.

For feedback and suggestions, write to us at [e-mail]